The short version of angiogenesis fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2026-05-13 and is reviewed periodically as new material appears.
Published studies on BPC-157 are dominated by animal models. Commonly used endpoints include healing of surgically induced lesions in the stomach, tendon-to-bone attachment after transection, and recovery from experimentally induced vascular or intestinal damage. Many of these reports come from a small number of research groups, and the peptide is often described as acting across a wide range of tissue types. That breadth is itself a point of discussion, since one molecule influencing many unrelated systems is unusual.
Human data are far more limited than animal data. A small number of clinical reports exist, generally with few participants and without the randomization or blinding expected in later-phase trials. No large, independently replicated human trial has appeared in the indexed peer-reviewed literature. Statements about effects in people therefore rest on extrapolation from animal work rather than on direct evidence, and the strength of that extrapolation remains an open question rather than a settled matter.
Once dissolved, the material is considerably less stable than the dry solid. Aqueous solutions are usually kept cold and used within a short window, and neutral or mildly acidic buffers are preferred over strongly alkaline conditions. Freeze-thaw cycles promote aggregation and loss of material to container surfaces, so dividing a batch into single-use aliquots is standard. Adsorption to plastic and glass can lower the measured concentration, meaning solution strength may need rechecking before an experiment.
Identity and purity are established with complementary methods rather than one test. Reverse-phase high-performance liquid chromatography separates the main peak from deletion sequences and oxidized variants, and its area percentage is the usual purity figure. Mass spectrometry confirms the expected molecular mass and can flag truncations or modifications that chromatography alone might miss. Amino acid analysis and peptide mapping add sequence-level confirmation, while residual counter-ion and water content are measured separately.
A freeze-dried sample is generally the most stable form and is commonly held at minus twenty degrees Celsius or lower for long-term keeping, with brief transfers at room temperature. The solid is hygroscopic, so vials are warmed to ambient temperature before opening to prevent condensation from degrading the contents. Light exposure and repeated temperature cycling are both avoided in routine handling. Storage over a desiccant is a common laboratory practice that limits moisture uptake during repeated access.
| Property | Value | Notes |
|---|---|---|
| Study species | Rodents, mainly rats | Most reports use surgically induced injury models |
| Typical administration route | Subcutaneous or intraperitoneal injection | Routes differ between reports, which complicates comparison |
| Human trial evidence | Limited, small-scale reports | No large randomized trial in indexed journals |
| Reported outcome categories | Mucosal healing, tendon repair, vascular recovery | Endpoints are not standardized across studies |
| Mechanism status | Not established | Proposed pathways lack direct confirmation |
BPC-157 is a synthetic peptide composed of fifteen amino acid residues, with the sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. Its name derives from body protection compound, a term used for a protein fraction identified in human gastric juice. Researchers in Zagreb first reported the pentadecapeptide in the early 1990s and described it as a stable fragment of that larger protein. The compound is also catalogued as PL 14736 and, in some commercial contexts, as bepecin. Its molecular formula is C62H98N16O22 and its monoisotopic mass is approximately 1419 daltons.
Most published work on BPC-157 consists of preclinical studies, including rodent models of tissue injury, gastrointestinal lesions, and vascular or tendon damage, together with in vitro cell assays. Reviews frequently note that the mechanisms proposed in these papers remain incompletely characterised and that findings have not been confirmed in large randomised human trials. The compound is widely sold as a research chemical rather than a licensed medicine, and labels commonly carry a statement that it is not for human use. Whether any of the reported animal effects translate to humans is an open question rather than an established result.
Terminology in the literature is not fully standardised. Papers and product listings use BPC-157, BPC 157, and the longer phrase stable gastric pentadecapeptide BPC 157 interchangeably, and synonyms such as bepecin or PL 14736 appear in older or company-linked publications. Purity claims and reported masses can also differ between sources because peptide preparations may include counterions, residual solvents, or bound water. This variability complicates direct comparison of results across studies and makes the exact identity and grade of a given sample worth verifying. Discussions of the compound should therefore specify the source, salt form, and stated purity where those are known.
Doses in the literature are usually expressed in micrograms or nanograms per kilogram of body weight. Investigators have administered the peptide by several routes, including injection and oral delivery, depending on the question asked. Route and dose vary widely across studies, which complicates direct comparison of results. Many papers report effects at low doses, but the absence of a standardized protocol limits generalization. Reporting practice differs between research groups.
Some properties, such as the peptide's sequence and molecular mass, are firmly established. Other claims, particularly about mechanism and clinical benefit, remain open questions. Proposed mechanisms include effects on nitric oxide signaling and on cell migration, but these are hypotheses supported by limited evidence. Reviewers often note that the field lacks large controlled human trials. Positive animal findings are best treated as signals for further study rather than as settled conclusions.
Most published studies examine BPC-157 in animal models rather than in humans. Common subjects include rats and mice, and researchers often use models of tissue injury, surgery, or induced inflammation. Reported endpoints include healing rates, blood vessel formation, and markers of tissue repair. These designs provide controlled comparisons, but findings in animals do not automatically transfer to people. Human clinical data remain limited and are frequently described as preliminary.
BPC-157 is a synthetic pentadecapeptide with the sequence GEPPPGKPADDAGLV, corresponding to a partial fragment of a larger protein detected in human gastric juice. The name derives from the parent protein designation BPC, an abbreviation of body protection compound, with 157 acting as a fraction or batch identifier used by the original investigators. Its molecular weight is approximately 1419 daltons, and the chain contains no unusual residues or disulfide bridges. In the literature it is described as a short, water-soluble fragment rather than a complete natural protein.
Most early work on this peptide originated in the 1990s from a research group in Zagreb, Croatia, relying on animal models and cell cultures. Reported observations included effects on gastrointestinal lesion healing, tendon fibroblast migration, and blood vessel formation under controlled laboratory conditions. These findings come predominantly from rodent studies and in vitro assays rather than from human trials. Controlled human data remain limited, and the degree to which animal results translate to human physiology is an open question rather than a settled fact.
Within the research literature, the peptide is discussed through several provisional mechanisms, including cytoprotection, modulation of growth factor signaling, and interaction with the nitric oxide system. None of these mechanisms is fully characterized, and no single pathway is universally accepted. Review articles typically note the gap between consistent animal findings and sparse human evidence. The compound is classified as a research chemical rather than an approved pharmaceutical, which shapes how studies are designed, funded, and reported.
Published work on BPC-157 spans several decades and covers a wide range of experimental models. Much of the early literature reports outcomes in animal studies involving induced injury to the gastrointestinal tract, tendons, and other tissues. The volume of preclinical reports is large, while controlled human trials remain scarce. This imbalance is a recurring point of discussion, because animal findings do not automatically translate into human effects. Reviews often note that study designs differ substantially across laboratories.
Interest in the peptide has grown through online communities that discuss self-administered use, which sits outside formal research settings. Regulatory status varies by country, and in many jurisdictions the compound is not approved as a therapeutic product. Questions about optimal routes of administration, long-term effects, and dose-response relationships remain open. Published pharmacokinetic data in humans are limited, and much of what circulates in popular discussion is extrapolated from animal work rather than measured directly in people.
BPC-157 is a synthetic peptide built from fifteen amino acids, referred to in the literature as a pentadecapeptide. Its sequence was derived from a larger protein found in human gastric juice, commonly called body protection compound. Researchers first described the fragment in the early 1990s and named it after the parent protein plus a numeric identifier. The peptide does not correspond to a single marketed medicine; it is primarily a laboratory research material. Suppliers distribute it as a lyophilized powder intended for experimental use.
===== Conservation burial ===== Conservation burial is a type of burial where burial fees fund the acquisition and management of new land to benefit native habitat, ecosystems and species. This usually involves a legal document such as a conservation easement. Such burials go beyond other forms of natural burial, which aim to prevent environmental damage caused by conventional burial techniques, by actually increasing benefits for the environment. The idea is for the burial process to be a net positive for the earth rather than just neutral. Scientists have argued that such burials could potentially generate enough funds to save every endangered species on the planet. The Green Burial Council certifies natural and conservation burial grounds in the U.S. and Canada.
Fasting blood sugar (glucose) level of: 110 to 125 mg/dL (6.1 mmol/L to 6.9 mmol/L) – WHO criteria 100 to 125 mg/dL (5.6 mmol/L to 6.9 mmol/L) – ADA criteria Glucose tolerance test: blood sugar level of 140 to 199 mg/dL (7.8 to 11.0 mM) 2 hours after ingesting a standardized 75 gram glucose solution (WHO and ADA criteria) Glycated hemoglobin (HbA1c) between 5.7 and 6.4 percent, i.e., 38.9 and 46.4 mmol/mol Levels above these limits would justify a diagnosis for diabetes.
BCN, also known as bicyclo[6.1.0]non-4-yne, is a copper-free click chemistry probe that enables highly efficient and completely orthogonal bioconjugation to complex macromolecules including peptides, nucleic acids and proteins, including monoclonal antibodies. The most recent and powerful application of this technology has been in the field of antibody-drug conjugates which results in targeted cancer therapeutics that have an improved therapeutic index, meaning they are more effective and better tolerated. BCN is well-suited for aqueous bioconjugations due to its high reactivity with its azide counterpart and its high hydrophilicity, relative to other metal-free click chemistry probes.
== History == Cold hemagglutination was first reported by Landsteiner in 1903 and found to occur in human beings in 1918. The association of cold hemagglutination with hemolysis was described in 1937 by Rosenthal and Corten. During the 1960s, Dacie and Schubothe published systematic descriptions of 16 CAD patients each. The auto antibodies responsible for hemagglutination at low temperatures, cold agglutinins (CA), may be found in the sera of healthy subjects as well as in patients with AIHA of the cold reactive types. CA bind to erythrocyte surface antigens at a temperature optimum of 0–4 °C. In contrast to polyclonal CA in healthy individuals, monoclonal CA often have a high-thermal amplitude, which contributes to their pathogenicity at temperatures approaching 37 °C. Binding of CA causes agglutination of erythrocytes and the antigen–antibody complex induces complement (C) activation and hemolysis. Essential clinical manifestations of primary CAD are hemolytic anemia and cold-induced circulatory symptoms. Exact estimates of the severity of anemia and the frequency of cold-induced symptoms, however, have not been provided until recent years.
Sources: en.wikipedia.org
=== Related diseases === Parenchymal disease occurs in 30% to 40% of those diagnosed with NM. The disease associated with the main functioning body of an organ, in this case the brain. Acute cerebellar ataxia is a rare initial presenting feature of NM, particularly in gastric cancer. Paraneoplastic cerebellar degeneration (PCD) is a well-known cause of cerebellar ataxia associated with neoplastic disorders, and commonly, with positivity for various anti-neuronal antibodies. Bilateral sensorineural hearing loss caused by complications with the vestibulocochlear nerves from onset of NM Subacute confusion: when functioning of the brain such as cognition deteriorates but at a less rapid rate than that of acute confusion
=== Hematologic involvement === Hematologic abnormalities are prevalent in MCTD. Mild lymphadenopathy affects 25–50% of patients, and it is frequently an early symptom of the disease. This usually subsides over time; however, it may reappear during flares. Between 50% and 75% of people with MCTD will experience anemia, lymphopenia, or leukopenia. Anemia of chronic disease is the most common type of anemia seen in MCTD. Thrombocytopenia can develop in MCTD but is less common than leukopenia or anemia.
The human penis is thicker than that of any other primate, both in absolute terms and relative to the rest of the body. Early research, based on inaccurate measurements, concluded that the human penis was also longer. In fact, the penis of the common chimpanzee is no shorter than in humans, averaging 14.4 cm (5.7 inches), and some other primates have comparable penis sizes relative to their body weight. The evolutionary reasons for the increased thickness have not been established. One explanation is that thicker penises are an adaptation to a corresponding increase in vaginal size. The vaginal canal is believed to have expanded in humans to accommodate the larger size of a newborn's skull. Women may then have sexually selected men with penises large enough to fit their vagina, to provide sexual stimulation and ensure ejaculation. Other evolutionary hypotheses to explain humans' relatively large penis length and girth include a sperm competition hypothesis and a mate competition hypothesis. The sperm competition hypothesis does not have much support as in other mammals where sperm competition is present, larger testes evolve, not larger penises. The mate competition hypothesis involves the prediction that a human with a larger penis would be able to displace the sperm of another. Studies have found that larger penises do not displace other sperm more effectively than smaller penises, but rather longer penises may ejaculate sperm inside the vagina in places that would be harder for a following penis to displace.
Sources: en.wikipedia.org
It is not authorized as a medicine in the United States or the European Union. Regulatory treatment varies by jurisdiction, and in several places it is handled as a research chemical. Therapeutic claims are not supported by large human trials.
Human evidence is sparse and comes from small reports rather than large trials. Sample sizes are generally too small to support firm conclusions. The published record does not contain an independently replicated randomized trial.
Several pathways have been proposed, including effects on nitric oxide signaling and vessel formation. Direct confirmation of a primary molecular target is lacking. Some findings rest on indirect measurements, which leaves the mechanism an open question.
Low temperature slows the chemical reactions, such as oxidation and hydrolysis, that break down a peptide chain. Water and oxygen are the main drivers of degradation, so a cold and dry environment extends usable life. Actual shelf life depends on the batch, the salt form, and the container.